Hikma Pharmaceuticals PLC - Depositary Receipt (Common Stock) - Income Statement (TTM)

Hikma Pharmaceuticals PLC - Depositary Receipt (Common Stock)
US ˙ OTCPK ˙ US4312881091

Income Statement (TTM)

Hikma Pharmaceuticals PLC - Depositary Receipt (Common Stock) Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.

All numbers are times 1,000,000 except per share units.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 2,316 2,341 2,383 2,425 2,489 2,553 2,552 2,550 2,534 2,517 2,624 2,731 2,803 2,875 2,946 3,017 3,072 3,127 3,172 3,216
Change (%) 1.06 1.79 1.76 2.64 2.57 -0.06 -0.06 -0.65 -0.65 4.25 4.08 2.64 2.57 2.47 2.41 1.82 1.79 1.42 1.40
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 1,134 1,128 1,150 1,173 1,212 1,252 1,247 1,242 1,247 1,252 1,313 1,374 1,421 1,468 1,518 1,569 1,640 1,712 1,772 1,832
Change (%) -0.53 1.99 1.96 3.37 3.26 -0.40 -0.40 0.40 0.40 4.87 4.65 3.42 3.31 3.44 3.33 4.56 4.36 3.50 3.39
% of Revenue 48.95 48.18 48.28 48.37 48.71 49.04 48.87 48.71 49.22 49.74 50.04 50.31 50.70 51.06 51.54 52.01 53.40 54.75 55.87 56.97
Gross Operating Profit 1,182 1,213 1,232 1,252 1,276 1,301 1,304 1,308 1,286 1,265 1,311 1,357 1,382 1,407 1,428 1,448 1,432 1,415 1,400 1,384
Change (%) 2.58 1.61 1.58 1.96 1.92 0.27 0.27 -1.64 -1.67 3.64 3.51 1.84 1.81 1.46 1.44 -1.14 -1.15 -1.10 -1.11
% of Revenue 51.05 51.82 51.72 51.63 51.29 50.96 51.13 51.29 50.78 50.26 49.96 49.69 49.30 48.94 48.46 47.99 46.60 45.25 44.13 43.03
SG&A 503 506 508 509 535 561 573 585 593 601 604 606 619 632 642 651 656 662 661 660
Change (%) 0.60 0.30 0.30 5.11 4.86 2.14 2.09 1.37 1.35 0.42 0.41 2.15 2.10 1.50 1.48 0.84 0.84 -0.15 -0.15
% of Revenue 21.71 21.61 21.30 20.99 21.49 21.97 22.46 22.94 23.41 23.88 23.00 22.19 22.08 21.98 21.78 21.58 21.37 21.17 20.84 20.52
R&D 134 137 136 134 138 143 148 153 148 144 142 139 144 149 148 146 144 141 147 153
Change (%) 2.62 -1.09 -1.11 3.36 3.25 3.50 3.38 -2.94 -3.03 -1.74 -1.77 3.60 3.47 -1.01 -1.02 -1.71 -1.74 4.26 4.08
% of Revenue 5.76 5.85 5.69 5.53 5.56 5.60 5.80 6.00 5.86 5.72 5.39 5.09 5.14 5.18 5.01 4.84 4.67 4.51 4.64 4.76
OpEx 1,790 1,801 1,830 1,858 1,925 1,992 1,997 2,002 2,010 2,019 2,120 2,220 2,235 2,250 2,274 2,299 2,409 2,519 2,578 2,636
Change (%) 0.59 1.58 1.56 3.61 3.48 0.25 0.25 0.42 0.42 4.98 4.74 0.68 0.67 1.09 1.08 4.78 4.57 2.32 2.27
% of Revenue 77.29 76.93 76.77 76.62 77.34 78.03 78.27 78.51 79.36 80.21 80.77 81.29 79.74 78.26 77.21 76.20 78.42 80.56 81.27 81.97
Operating Income 526 540 554 567 564 561 554 548 523 498 504 511 568 625 672 718 663 608 594 580
Change (%) 2.66 2.50 2.44 -0.53 -0.53 -1.16 -1.17 -4.56 -4.78 1.31 1.29 11.15 10.04 7.44 6.92 -7.66 -8.30 -2.30 -2.36
% of Revenue 22.71 23.07 23.23 23.38 22.66 21.97 21.73 21.49 20.64 19.79 19.23 18.71 20.26 21.74 22.79 23.80 21.58 19.44 18.73 18.03
Interest Expense -38 -41 -42 -42 -42 -43 -47 -51 -55 -59 -64 -70 -72 -73 -73 -73 -74 -75 -73 -71
Change (%) 7.89 1.22 1.20 1.19 1.18 9.30 8.51 7.84 7.27 9.32 8.53 2.14 2.10 -0.00 -0.00 1.37 1.35 -2.67 -2.74
% of Revenue -1.64 -1.75 -1.74 -1.73 -1.71 -1.68 -1.84 -2.00 -2.17 -2.34 -2.46 -2.56 -2.55 -2.54 -2.48 -2.42 -2.41 -2.40 -2.30 -2.21
Net Income 472 431 449 467 444 421 384 346 267 188 167 146 168 190 238 285 322 359 365 371
Change (%) -8.69 4.18 4.01 -4.93 -5.18 -8.91 -9.78 -22.83 -29.59 -11.17 -12.57 15.07 13.10 25.00 20.00 12.98 11.49 1.67 1.64
% of Revenue 20.38 18.41 18.84 19.26 17.84 16.49 15.03 13.57 10.54 7.47 6.36 5.35 5.99 6.61 8.06 9.45 10.48 11.48 11.51 11.54

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista